Tirzepatide Injection Injury Lawsuit Lawyers

Nationwide Tirzepatide Injection Recall: Contamination Risks, Serious Injuries, and Potential Lawsuits

What Parker Waichman LLP Found

• Nationwide recall: Apothecary Pharma recalled 22 lots of compounded tirzepatide injections because sterility could not be assured.
• Previous FDA warnings: Federal regulators had already identified deficiencies in the pharmacy’s sterile drug preparation practices.
• Potential serious injuries: Contaminated injections can cause abscesses, bloodstream infections, sepsis, and other complications.
• Possible legal claims: Patients harmed by contaminated injections may be able to pursue compensation for medical expenses, lost income, and other damages.
• Important evidence: Medication vials, lot numbers, prescription records, laboratory results, and medical documentation may help establish a legal claim.

Apothecary Pharma recalls 22 lots of compounded GLP-1 weight-loss injections over sterility concerns following previous FDA warnings. Patients who suffer infections or other serious complications may have grounds to pursue compensation.

Compounded tirzepatide injections distributed nationwide by Apothecary Pharma LLC have been recalled because the manufacturer could not provide adequate assurance that the medications were sterile. The voluntary recall, initiated September 24, 2026, involves 22 lots of prescription injections used by patients seeking treatment for obesity, weight management, and Type 2 diabetes. The U.S. Food and Drug Administration (FDA) classified the action as a Class II recall on October 10, 2026.

The recall raises significant concerns because injectable medications bypass many of the body’s natural defenses against bacteria and other harmful microorganisms. When an injectable drug is contaminated, patients may face infections, bloodstream complications, hospitalization, and potentially life-threatening medical emergencies. Although the recall does not establish that every affected vial was contaminated or that patients have suffered injuries, the inability to guarantee sterility warrants serious attention.

The recall is particularly concerning because Apothecary Pharma previously received an FDA warning letter identifying serious deficiencies in its sterile drug production practices. Patients who received injections from the affected lots should understand the potential health consequences, how to identify recalled medication, and when an injury may justify a product liability lawsuit.

Apothecary Pharma’s Nationwide Tirzepatide Recall and the FDA’s Findings

Apothecary Pharma LLC, a compounding pharmacy based in Cary, North Carolina, initiated the voluntary recall after concerns arose about the sterility of certain compounded tirzepatide injections. The affected medication contains tirzepatide, the active pharmaceutical ingredient used in FDA-approved medications marketed under the brand names Mounjaro and Zepbound.

The FDA’s Class II designation means exposure to the recalled product could cause temporary or medically reversible adverse health consequences, while the probability of serious adverse consequences is considered remote. However, that classification does not mean every patient faces the same risk or that severe complications are impossible. A patient’s medical condition, the nature of any contamination, and the timing of treatment can substantially influence the outcome.

The recall follows an FDA warning letter issued in December 2025 concerning Apothecary Pharma’s manufacturing and compounding practices. Federal regulators identified serious deficiencies involving medications intended to be sterile and warned that these conditions placed patients at risk.

These earlier findings may become important when evaluating potential litigation. Attorneys investigating injury claims may examine whether the pharmacy corrected previously identified problems, maintained adequate quality controls, conducted appropriate sterility testing, and complied with applicable federal and state compounding requirements.

Recalled Tirzepatide Injection Lot Numbers and Expiration Information

The recalled product is Apothecary Pharma Tirzepatide Injection, 18 mg/mL, supplied in a 4-mL sterile multidose vial. According to the reported FDA recall information, 22 vials are affected, spanning the following lot numbers and beyond-use dates (BUDs).

Patients should compare the lot number on their medication vial with this information. A beyond-use date indicates when a compounded medication should no longer be used under its assigned storage conditions. It does not establish that a recalled medication was safe before that date.

Patients should also understand that this recall concerns specified compounded tirzepatide products manufactured by Apothecary Pharma. It does not constitute a recall of all tirzepatide products or FDA-approved Mounjaro and Zepbound medications.

Serious Health Risks Associated With Potentially Contaminated GLP-1 Injections

Sterility is essential for injectable medications because microorganisms introduced beneath the skin can cause infections that spread beyond the original injection site. Contamination may involve bacteria, fungi, or other microorganisms capable of causing illness.

An injection-site infection may initially cause redness, warmth, tenderness, swelling, or drainage. Some patients develop abscesses, which are collections of infected material that may require antibiotics, drainage, or surgical treatment. Infections can also spread into surrounding tissue, producing cellulitis and additional complications.

More severe infections can enter the bloodstream and cause bacteremia or sepsis. Sepsis occurs when the body’s response to infection produces life-threatening organ dysfunction. Patients may experience fever, chills, rapid breathing, confusion, low blood pressure, or worsening weakness. Severe cases can require intensive care, intravenous antibiotics, and prolonged hospitalization.

People with diabetes, weakened immune systems, or certain underlying medical conditions may be especially vulnerable to complications from infection. Importantly, these are potential consequences of contaminated injections, not confirmed injuries attributed to the recalled Apothecary Pharma lots.

Patients experiencing fever, spreading redness, unusual injection-site pain, or other concerning symptoms should seek prompt medical assessment. Confusion, breathing difficulty, fainting, or signs of severe infection require emergency medical attention.

Compounded GLP-1 Medications and Their Differences From FDA-Approved Drugs

Compounding pharmacies prepare medications by combining, mixing, or altering ingredients to address an individual patient’s medical needs. These services can be valuable when an FDA-approved medication is unavailable in a necessary formulation or contains an ingredient a patient cannot tolerate.

However, compounded drugs do not undergo the same premarket FDA approval process as commercially manufactured medications. The FDA does not individually evaluate compounded formulations for safety, effectiveness, and quality before distribution.

Demand for compounded GLP-1 medications increased during shortages of popular diabetes and weight-loss treatments. Following the resolution of the tirzepatide and semaglutide shortages, federal regulators imposed additional limitations on the circumstances under which pharmacies could produce essentially identical copies of commercially available medications.

Compounded medications are not inherently unsafe, but pharmacies must follow applicable preparation, sanitation, testing, and quality-control requirements. Failures involving sterile compounding can create significant patient risks, particularly when medications are injected repeatedly over several weeks.

Potential Product Liability Lawsuits Involving Recalled Tirzepatide Injections

Patients who suffer injuries after receiving recalled tirzepatide injections may have grounds to investigate a product liability or negligence claim. Potential defendants could include the compounding pharmacy and other entities whose conduct contributed to the injury, depending on the facts and applicable law.

A lawsuit may examine whether the medication was contaminated, whether the pharmacy failed to maintain appropriate sterile production conditions, and whether adequate testing or quality-control measures could have prevented distribution of an unsafe product.

The FDA’s previous warning letter may provide relevant evidence concerning notice of manufacturing problems. However, a regulatory violation or recall alone does not automatically establish liability. Injured patients generally must demonstrate a legally recognized basis for liability, actual damages, and a causal connection between the defendant’s conduct or product and their injuries.

Recoverable damages may include past and future medical expenses, hospitalization costs, lost wages, diminished earning capacity, physical pain, emotional suffering, and other losses permitted under applicable state law.

Preserving Evidence After Exposure to Recalled Tirzepatide

Patients who possess a recalled vial should not administer additional doses from it. They should contact their prescribing healthcare professional promptly to discuss alternative treatment and safe handling instructions.

Anyone who develops symptoms after receiving an affected injection should tell their healthcare provider the medication’s name, source, lot number, and injection date. Medical records, blood cultures, wound cultures, and other diagnostic findings may help determine whether an infection occurred and identify its possible source.

Patients considering legal action should preserve the medication packaging, prescription records, purchase receipts, pharmacy communications, photographs, and treatment documentation. They should not attempt to test or open a vial themselves. An attorney can help arrange appropriate evidence preservation without interfering with necessary medical care.

Early documentation can be important because evidence may become unavailable over time, and deadlines for filing injury claims vary by state.

Frequently Asked Questions About Tirzepatide Recall Lawsuits

Can I File a Lawsuit if I Became Sick After Receiving a Recalled Tirzepatide Injection?

You may have grounds for a lawsuit if you experienced an infection or another medically documented injury caused by a defective tirzepatide injection. A claim generally requires evidence connecting the medication to your injuries. Medical records, laboratory testing, prescription histories, and the recalled product’s lot number can help establish that connection. An attorney can investigate whether the compounding pharmacy failed to follow applicable safety requirements and whether those failures contributed to your medical complications.

What Compensation Is Available in a Contaminated GLP-1 Injection Lawsuit?

Compensation depends on the severity of the injury, applicable state law, and the evidence supporting the claim. Recoverable damages may include emergency treatment, hospitalization, antibiotics, surgery, rehabilitation, lost wages, and future medical expenses. Patients who experience lasting complications may also seek damages for reduced earning capacity, chronic pain, emotional distress, and diminished quality of life. Punitive damages may be available in limited circumstances when the evidence satisfies applicable legal standards.

Can I Sue Apothecary Pharma if I Received a Recalled Injection but Have No Symptoms?

Receiving recalled medication does not automatically establish a compensable personal injury claim. Most product liability lawsuits require proof of an actual injury and legally recoverable damages. Certain jurisdictions recognize limited claims involving medical monitoring or other economic losses, but these claims depend heavily on state law. Patients without symptoms should still contact their prescribing healthcare professional, document their exposure, and preserve relevant medication information.

How Can I Prove That a Recalled Tirzepatide Injection Caused My Infection?

Establishing causation may require examining when symptoms developed, where the medication was injected, the type of infection diagnosed, and whether other possible sources of infection exist. Physicians may use wound cultures, blood cultures, imaging, and additional testing to identify the infection. Attorneys may also obtain pharmacy production records, distribution information, and quality-control documentation. The strength of a case often depends on how consistently the medical and manufacturing evidence supports a connection between the injection and the injury.

How Long Do I Have to File a Tirzepatide Recall Lawsuit?

The deadline depends on the state whose law governs the claim and the circumstances surrounding the injury. Personal injury statutes of limitations vary, and certain claims may be subject to additional notice requirements or filing restrictions. In some circumstances, a discovery rule may affect when the limitations period begins. Because evidence can disappear and legal deadlines may expire, patients who suffered complications should seek legal guidance promptly rather than waiting for the recall investigation to conclude.

Free Consultation With Parker Waichman LLP About Recalled Tirzepatide Injections

Patients who developed infections, sepsis, abscesses, or other serious complications after receiving recalled compounded tirzepatide injections deserve answers about what happened and whether their injuries could have been prevented

Parker Waichman LLP is a national personal injury law firm representing individuals and families harmed by dangerous medications, defective products, and negligent conduct. Our attorneys can review the circumstances surrounding a recalled injection, examine relevant medical documentation, investigate potential liability, and determine whether a claim for financial compensation may be available.

Call Parker Waichman LLP at 1-800-YOUR-LAWYER (1-800-968-7529) for a free consultation. Our firm helps injured consumers nationwide understand their legal rights and options for pursuing compensation. Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.